Zydus Lifesciences: Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted for Review by UDFDA
Zydus Lifesciences (ZYDUSLIFE) filed a disclosure titled "Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted for Review by UDFDA". The company is valued at about ₹1.13 lakh crore.
What happened
Zydus Lifesciences (ZYDUSLIFE) filed a disclosure with the exchanges on 13 October 2026 at 09:50 AM titled "Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted for Review by UDFDA".
Company snapshot
Zydus Lifesciences is a large-cap company in the Healthcare sector, with a market value of about ₹1.13 lakh crore.
The stock last traded at ₹1,137.2, against a 52-week range of ₹835.5–₹1,232.1 (7.7% below the high).
Before this filing the shares had moved −0.9% over the month and −1.2% over three months. Average daily turnover over the last 20 sessions was about ₹177 crore.
Promoters held 75.01% at the end of Q1 FY27. Foreign institutions owned 6.88% and domestic institutions 11.27%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 6,574 | 1,466.8 | 14.58 |
| Q2 FY26 | 6,123 | 1,258.6 | 12.51 |
| Q3 FY26 | 6,865 | 1,042.1 | 10.36 |
| Q4 FY26 | 7,587 | 1,272.5 | 12.65 |
| Q1 FY27 | 8,017 | 939.8 | 9.35 |
What history shows
This is not the company's first approval disclosure: BCEIE has 5 earlier filings of this kind on record since May 2026.
After those filings, the stock fell 0.2% on average the next trading day and was up 3.4% on average after five days (3 filings with price data).
Across 108 similar disclosures by other Healthcare companies, shares moved +0.5% on average the next day and +0.9% over five days; 53% of them rose the next day.
Market-wide, 1,501 approval filings with an impact score of 50 or more saw an average next-day move of +0.2%, with 47% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 26 Sept 2026 | USFDA inspection of pharmacovigilance and post marketing system… | −0.3% | −3.7% |
| 21 Aug 2026 | A press release dated August 21, 2026, titled "Zydus announces final… | −0.4% | +7.5% |
| 4 Aug 2026 | A press release dated August 04, 2026, titled "Zydus announces Final… | +0.0% | +6.2% |
In the news
Recent coverage elsewhere (links open the original publisher):
- Zydus Lifesciences, MSN Laboratories Launch First Generic of Adempas in US
- Mankind Pharma, Zydus Lifesciences among top losers, fall up to 3% after Supreme Court asks Centre to...
- ZYDUSLIFE Outlook for the Week
- Zydus Lifesciences Extends Sunshine Healthcare Lanka 50:50 JV Investment Deadline To December 2026
- Zydus Lifesciences zooms 4% after getting USFDA nod for Dapagliflozin Tablets, 5 mg & 10 mg
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.